冬季呼吸道疾病高发，大家对鼻塞症状更是司空见惯。很多人被反复鼻塞困扰、乱服感冒药，症状不见 好反而延误了鼻窦炎的治疗。鼻窦炎不及时治疗，可能发展为慢性鼻窦炎、中耳炎，甚至引发颅内感 染，但早识别、早干预，通过规范治疗和居家护理，绝大多数都能痊愈。 感冒引起的鼻塞和鼻窦炎如何区分？北京大学人民医院耳鼻咽喉头颈外科主任医师王旻提醒：这两种病 症状很像，但病理和治疗方案完全不同，5分钟教你精准识别。 冬季感冒 更易引发鼻窦炎 冬季气温低、空气干，鼻腔黏膜抵抗力下降，病毒容易入侵引发感冒。加之感冒后鼻腔黏膜充血水肿， 堵塞鼻窦和鼻腔的通道，鼻窦里的分泌物排不出去，细菌滋生就会发炎。此外，冬季雾霾、粉尘多，持 续刺激鼻腔和鼻窦黏膜，加重炎症，形成"越堵越感染"的循环。 普通感冒和鼻窦炎的核心区别在"病变部位"和"病程"：感冒是鼻腔黏膜急性病毒感染，鼻窦炎是鼻腔周 围骨性空腔（鼻窦）的炎症，常由感冒没控制好发展而来。7天是关键分水岭，记住两个判断点： 持续超7天 鼻塞、流涕等症状超过7天没好转，甚至加重，大概率是鼻窦炎。 好转后又加重 感冒3至5天症状缓解，6至7天突然变重，比如鼻塞加剧、鼻涕从清涕变成黄绿色脓涕、 开始 ...

长风药业(02652)发布公告，公司布地奈德鼻喷雾剂的上市许可申请已获中华人民共和国国家药品监督 管理局受理。 鼻喷雾剂是技术门槛较高的复合制剂。凭借鼻腔给药技术平台，公司已建立涵盖多种适应症及呼吸道与 鼻炎病症全疗程管理的全面产品矩阵。公司在此方面的现有产品组合包括： 糠酸莫米松鼻喷雾剂：适用于成人及3岁及以上儿童的过敏性鼻炎的一线药物; 布地奈德鼻喷雾剂(该产品)：适用于6岁及以上患者，针对季节性急性发作、常年性维持治疗及鼻息肉; 及 奥洛他定╱莫米松鼻喷雾剂：针对12岁及以上青少年及成人中重度过敏性鼻炎症状。 布地奈德鼻喷雾剂申请受理，进一步丰富公司在过敏性鼻炎领域的产品管线，彰显公司深化呼吸系统吸 入治疗领域布局的决心及能力，为患者提供优质的治疗选择。集团将积极与NMPA沟通，并根据监管要 求推进后续审查程序。 氮 斯汀氟替卡松鼻喷雾剂(舒霏敏)：国内首款抗组织胺-类固醇复合鼻喷雾剂，于2023年纳入《国家医 保药品目录》(国家医保目录); ...

智通财经APP讯，长风药业(02652)发布公告，公司布地奈德鼻喷雾剂的上市许可申请已获中华人民共和 国国家药品监督管理局受理。 鼻喷雾剂是技术门槛较高的复合制剂。凭借鼻腔给药技术平台，公司已建立涵盖多种适应症及呼吸道与 鼻炎病症全疗程管理的全面产品矩阵。公司在此方面的现有产品组合包括： 氮䓬斯汀氟替卡松鼻喷雾剂(舒霏敏®)：国内首款抗组织胺-类固醇复合鼻喷雾剂，于2023年纳入《国家 医保药品目录》(国家医保目录); 糠酸莫米松鼻喷雾剂：适用于成人及3岁及以上儿童的过敏性鼻炎的一线药物; 布地奈德鼻喷雾剂(该产品)：适用于6岁及以上患者，针对季节性急性发作、常年性维持治疗及鼻息肉; 及 奥洛他定╱莫米松鼻喷雾剂：针对12岁及以上青少年及成人中重度过敏性鼻炎症状。 布地奈德鼻喷雾剂申请受理，进一步丰富公司在过敏性鼻炎领域的产品管线，彰显公司深化呼吸系统吸 入治疗领域布局的决心及能力，为患者提供优质的治疗选择。集团将积极与NMPA沟通，并根据监管要 求推进后续审查程序。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 CF PharmTech, Inc. 長風藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2652） 自願公告 NMPA受理布地奈德鼻噴霧劑上市許可申請 本公告乃由長風藥業股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以知會股東及潛在投資者有關本集團之最新研發進展。 緒言 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司布地奈德鼻噴霧劑（「該 產品」）的上市許可申請（「申請」）已獲中華人民共和國國家藥品監督管理局 （「NMPA」）受理。茲公告相關資訊如下： 1 產品名稱 : 布地奈德鼻噴霧劑 申請類型 : 上市許可申請 受理號 : CYHS2600272/CYHS2600273 申請人 ： 本公司 規格 : 每噴32微克（每瓶120噴）╱每噴64微克（每瓶 120噴） 適應症 ： 治療(1)季節性及常年性過敏性鼻炎；(2)常年性 非過敏性鼻炎；及(3 ...

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Group 1 - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for Rivaroxaban tablets [1] - Rivaroxaban is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1][2] - The company has invested approximately RMB 8.2 million in the research and development of Rivaroxaban [1] Group 2 - The market for Rivaroxaban in the U.S. generated approximately $8.13 billion in sales in 2023, with projected sales of about $6.33 billion for the first three quarters of 2024 [2] - Competitors in the U.S. market for Rivaroxaban include Janssen Pharmaceuticals and several generic manufacturers [2] Group 3 - The FDA has also approved the ANDA for Mometasone Furoate nasal spray by Zhejiang Xinyi Ruijue Pharmaceutical [4] - Mometasone Furoate is used for the prevention and treatment of seasonal allergic rhinitis in adolescents and adults, as well as for chronic sinusitis with nasal polyps in adults [5] - The nasal spray generated approximately $43.7 million in sales in the U.S. in 2023, with projected sales of about $33.45 million for the first three quarters of 2024 [5]

Core Viewpoint - The article discusses the significant impact of antitrust penalties on the financial performance of Xianju Pharmaceutical and other companies involved in price-fixing agreements for dexamethasone phosphate raw materials during the COVID-19 pandemic [1][3]. Group 1: Antitrust Penalties - Xianju Pharmaceutical was fined 195 million yuan for monopolistic practices, which accounts for 4.88% of its 2024 revenue and 49.17% of its net profit [1]. - Tianyao Pharmaceutical and Lianhuan Pharmaceutical were also penalized, with fines of 69.19 million yuan and 61.04 million yuan, respectively [1]. - The companies formed a price alliance, raising the price of dexamethasone phosphate from 0.35 yuan to a peak of 98.76 yuan, an increase of nearly 282 times [1]. Group 2: Financial Impact on Companies - In 2024, Xianju Pharmaceutical's net profit fell by 29.46% to 397 million yuan, largely due to the antitrust fine [2][4]. - The cash flow from operating activities for Xianju Pharmaceutical decreased by 33.05%, and cash reserves dropped by 16.76% [4]. - Tianyao Pharmaceutical's revenue in 2024 was 3.215 billion yuan, down 15%, but its net profit increased by 14% due to the fine being accounted for in 2025 [6][7]. Group 3: Market Adjustments and Strategies - Xianju Pharmaceutical is shifting its product structure and expanding into overseas markets to mitigate the impact of declining revenues from dexamethasone products [5]. - The company is focusing on high-margin areas such as respiratory and dermatological products, with sales in respiratory products growing by 31% in 2024 [5]. - Tianyao Pharmaceutical's steroid raw material business also saw a revenue decline of 16.9% in 2024, indicating broader market pressures [7]. Group 4: Ongoing Challenges - Tianyao Pharmaceutical has faced multiple antitrust penalties over the past four years, indicating a pattern of regulatory scrutiny [8]. - Lianhuan Pharmaceutical's future penalties remain uncertain as it plans to appeal the decision, highlighting the ongoing challenges within the industry [8].

Core Viewpoint - The announcement by the company regarding the approval of its fluticasone propionate nasal spray marks a significant step in breaking the market monopoly of foreign products in the domestic allergic rhinitis treatment sector [2]. Group 1: Product Development and Market Position - The fluticasone propionate nasal spray is the first domestic generic product to be launched in China and has been included in the national medical insurance and essential drug lists [2]. - The company has established itself as one of the leading firms in the domestic market for allergic rhinitis treatments, with a comprehensive product pipeline [2]. - The respiratory and critical care segment generated approximately HKD 1.71 billion in revenue last year, reflecting a nearly 27% year-on-year growth [2]. Group 2: Future Development Strategy - The company plans to continue its strategy of independent research and global expansion, focusing on developing a comprehensive product cluster for chronic airway diseases and critical care [3].

Core Viewpoint - The announcement of the approval of the fluticasone propionate nasal spray by Yuan Da Pharmaceutical marks a significant milestone for the company, as it is the first domestic generic version in China, expected to disrupt the market dominated by foreign products and provide more affordable treatment options for patients with allergic rhinitis [1][4]. Group 1: Market Opportunity - The fluticasone propionate nasal spray is a preferred treatment for allergic rhinitis in China, which has a high prevalence of approximately 17.6% among adults, translating to nearly 250 million patients [4][5]. - The nasal preparation market in China is projected to reach nearly 3.5 billion RMB in 2023, with a compound annual growth rate (CAGR) of 10.4% from 2019 to 2023 [4]. - The market for fluticasone propionate nasal spray is expected to reach 2.46 billion RMB by 2025, indicating substantial growth potential [4]. Group 2: Competitive Landscape - The current market for nasal corticosteroids is largely dominated by foreign companies, with Pfizer and Merck holding about half of the market share in 2023, highlighting a significant opportunity for domestic alternatives [5]. - Yuan Da Pharmaceutical's successful launch of the budesonide nasal spray, another first generic product, demonstrates the potential for domestic products to gain market share and disrupt foreign dominance [5][6]. Group 3: Product Pipeline and Innovation - Yuan Da Pharmaceutical has a comprehensive pipeline for allergic rhinitis treatments, including the upcoming Ryaltris® combination nasal spray, which is expected to meet the needs of patients with varying severity of allergic rhinitis [7][8]. - The company is also developing STC3141, an innovative product targeting sepsis, which has shown promising clinical results and addresses a significant unmet medical need in a market projected to reach 5.627 billion USD by 2030 [9]. - The focus on both self-developed and globally expanded research and development aims to solidify the company's position in the respiratory and critical care sectors [9].